Dual GPX4/PARP inhibitor YHD-26 exerts potent antitumor activity against triple-negative breast cancer via ferroptosis and DNA damage synergy.
- DOI
- 10.1016/j.bcp.2026.118433
- Published
- 2026 Sep 4
- Container
- Biochemical pharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bcp.2026.118433,
title = {Dual GPX4/PARP inhibitor YHD-26 exerts potent antitumor activity against triple-negative breast cancer via ferroptosis and DNA damage synergy.},
author = {Bao H and Lai Y and Zhao X and Chen W and Chen Z and Guo Y and He Z and Wu H and Yao D},
year = {2026},
journal = {Biochemical pharmacology},
doi = {10.1016/j.bcp.2026.118433},
url = {https://doi.org/10.1016/j.bcp.2026.118433}
}RIS
TY - JOUR TI - Dual GPX4/PARP inhibitor YHD-26 exerts potent antitumor activity against triple-negative breast cancer via ferroptosis and DNA damage synergy. AU - Bao H AU - Lai Y AU - Zhao X AU - Chen W AU - Chen Z AU - Guo Y AU - He Z AU - Wu H AU - Yao D PY - 2026 JO - Biochemical pharmacology DO - 10.1016/j.bcp.2026.118433 UR - https://doi.org/10.1016/j.bcp.2026.118433 ER -
APA
H, B., Y, L., X, Z., W, C., Z, C., Y, G., Z, H., H, W., & D, Y. (2026). Dual GPX4/PARP inhibitor YHD-26 exerts potent antitumor activity against triple-negative breast cancer via ferroptosis and DNA damage synergy.. Biochemical pharmacology. https://doi.org/10.1016/j.bcp.2026.118433
Source records
- pubmed · retrieved 2026-09-25T08:41:52.639Z